Aisling’s Schiff on life sciences investing and today’s investment cycle

Top of Mind Healthcare Venture
Andrew Schiff, managing partner, Aisling Capital. Photo courtesy of the firm.
Aisling Capital closed a $280 million fourth fund in November with the goal of pursuing mid- to late-stage clinical opportunities. And there is no secret why. “This is a target-rich environment,” said Managing Partner Andrew Schiff. “There are lots of ...

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

This content is available for Venture Capital subscribers only. Request a free trial to get access for a limited period

Venture Capital

Subscribe Now Request Trial

If you already have an active Venture Capital subscription, please sign in to view this article.